Enzychem Lifesciences Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Ki-Young Sohn

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	5.1%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 13

There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price

Aug 13

Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt

May 09

If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns

Feb 17

CEO

Ki-Young Sohn

no data

Görev süresi

Ki-Young Sohn serves as the Chairman and Chief Executive Officer at Enzychem Lifesciences Corporation. Ki-Young Sohn holds MBA from graduate School of Business, Dept. of Business Administration Korea Unive...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ki-Young Sohn	Chairman & Chief Executive Officer	no data	Veri yok	5.1% ₩ 5.2b
G. Alexander Fleming	Member of Corporate Advisory Committee & CTO	2.8yrs	Veri yok	Veri yok
Do-Young Lee	Chief Scientific Officer & Member of the Board of Directors	no data	Veri yok	Veri yok
Myung-Hwan Kim	CMO & Director	7.7yrs	Veri yok	Veri yok
John Choi	Executive Director	no data	Veri yok	Veri yok
Jae-Yong Lee	VP & Executive Director	no data	Veri yok	Veri yok
Jong-Koo Kang	Director	7.7yrs	Veri yok	Veri yok
Hye-Kyung Kim	Vice Chairman	no data	Veri yok	0.080% ₩ 82.2m
Sang-Hee Kim	Director	7.7yrs	Veri yok	Veri yok
Sang-Gon Ko	Director	7.7yrs	Veri yok	Veri yok
Jae-Wha Kim	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Crawford	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: A183490 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Enzychem Lifesciences Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

No independent directors

No independent directors

Recent updates

Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price

New minor risk - Market cap size

Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt

Enzychem Lifesciences Corporation (KOSDAQ:A183490) announces an Equity Buyback for KRW 10,000 million worth of its shares.

Enzychem Lifesciences Corporation (KOSDAQ:A183490) announces an Equity Buyback for KRW 10,000 million worth of its shares.

Full year 2023 earnings released: ₩110 loss per share (vs ₩316 loss in FY 2022)

Full year 2022 earnings released: ₩316 loss per share (vs ₩533 loss in FY 2021)

No independent directors

No independent directors

Enzychem Lifesciences Corporation to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Enzychem Lifesciences Announces Database Lock for Phase 2 Study of Ec-18 in Chemoradiation-Induced Oral Mucositis

Enzychem Lifesciences Corporation announced that it has received KRW 6.5006487 billion in funding

Enzychem Lifesciences Corporation announced that it has received KRW 23.5014976 billion in funding

Enzychem Lifesciences Corporation announced that it expects to receive KRW 6.5006487 billion in funding

Enzychem Lifesciences Corporation announced that it expects to receive KRW 23.5014976 billion in funding

If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns

New 90-day low: ₩90,200

New 90-day low: ₩95,000

New 90-day high - ₩127,000

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş